Pharmanomics: 如何摧毁全球健康的制药业 (有声书)

English | November 14, 2023 | ASIN: B0CM45VR5C | M4B@128 kbps | 9h 59m | 555 MB

In Pharmanomics, investigative journalist Nick Dearden digs down into the way we produce our medicines and finds that Big Pharma is failing us, with catastrophic consequences.

Big Pharma is more interested in profit than health. This was made clear as governments rushed to produce vaccines during the Covid pandemic. Behind the much-trumpeted scientific breakthroughs, major companies found new ways of gouging billions from governments in the West while abandoning the Global South. But this is only the latest episode in a long history of financializing medicine—from Purdue's rapacious marketing of highly addictive OxyContin through Martin Shkreli's hiking the price of a lifesaving drug to the 4.5 million South Africans needlessly deprived of HIV/AIDS medication.

Since the 1990s, Big Pharma has gone out of its way to protect its property through the patent system. As a result, the business has focused not on researching new medicines but on building monopolies. This system has helped restructure our economy away from invention and production in order to benefit financial markets. It has fundamentally reshaped the relationship between richer and poorer countries, as the access to new medicines and the permission to manufacture them is ruthlessly policed. In response, Dearden offers a pathway to a fairer, safer system for all.

在《Pharmanomics》中，调查记者Nick Dearden深入探究了我们如何生产药品的方式，并发现制药业正让我们受损，后果严重。 制药业更关心利润而不是健康。这在新冠疫情期间政府匆忙生产疫苗时变得明显。在备受推崇的科学突破背后，大型企业找到了新的方式向西方国家政府敲诈数十亿美元，同时放弃了对全球南方的支持。但这是制药业金融化医疗历史中的最新篇章——从普渡公司贪婪地营销高度上瘾的奥西可定，到马丁·斯克雷利提高救命药物的价格，再到450万南非人因缺乏艾滋病治疗而无谓地受苦。 自1990年代以来，制药业一直竭尽全力通过专利系统保护自己的利益。因此，业务的重点不再是研发新药，而是建立垄断权。这一系统帮助我们从发明和生产转向更有利于金融市场的发展。它从根本上重塑了富国与穷国之间的关系，因为获取新型药物的权限以及制造它们的能力被无情地监管。对此，Dearden 提出了一个公平且安全的系统途径。

---

Download from free file storage

 Download from nitroflare.com  Download from ddownload.com

---

我要反馈

---

本站不对文件进行储存，仅提供文件链接，请自行下载，本站不对文件内容负责，请自行判断文件是否安全，如发现文件有侵权行为，请联系管理员删除。